Heron Therapeutics Files Q1 2025 10-Q
Ticker: HRTX · Form: 10-Q · Filed: 2025-05-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report, customer-concentration
Related Tickers: HRTX
TL;DR
HRTX Q1 2025 10-Q is in: Revenue & expenses detailed, RSU & AOCI updates.
AI Summary
Heron Therapeutics, Inc. (HRTX) filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance, including sales revenue and general and administrative expenses for the first quarter of 2025. The filing also details information regarding restricted stock units, accumulated other comprehensive income, and fair value measurements.
Why It Matters
This filing provides investors with an update on Heron Therapeutics' financial health and operational performance for the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — The filing contains information on customer concentration risk and financial performance, which can indicate potential business risks.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial performance)
- 2025-03-31 — Balance Sheet Date (End of the reporting period)
Key Players & Entities
- HERON THERAPEUTICS, INC. (company) — Filer
- HRTX (company) — Ticker Symbol
- 20250331 (date) — Reporting Period End Date
- 20250506 (date) — Filing Date
- Hercules Capital Inc (company) — Mentioned in relation to a date
FAQ
What was Heron Therapeutics' net sales revenue for the first quarter of 2025?
The filing indicates 'us-gaap:SalesRevenueNetMember' for the period 2025-01-01 to 2025-03-31, but the specific dollar amount is not provided in this excerpt.
Does Heron Therapeutics face significant customer concentration risk?
Yes, the filing mentions 'us-gaap:CustomerConcentrationRiskMember' in relation to both 'us-gaap:SalesRevenueNetMember' and 'us-gaap:AccountsReceivableMember' for the period 2025-01-01 to 2025-03-31.
What is the company's fiscal year end?
Heron Therapeutics, Inc.'s fiscal year ends on 1231.
What were the General and Administrative Expenses for Q1 2025?
The filing references 'us-gaap:GeneralAndAdministrativeExpenseMember' for the period 2025-01-01 to 2025-03-31, but the specific dollar amount is not detailed in this excerpt.
Are there any details about restricted stock units (RSUs) in the filing?
Yes, the filing mentions 'us-gaap:RestrictedStockUnitsRSUMember' for the period 2025-01-01 to 2025-03-31.
From the Filing
0000950170-25-063971.txt : 20250506 0000950170-25-063971.hdr.sgml : 20250506 20250506074521 ACCESSION NUMBER: 0000950170-25-063971 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 25915280 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 10-Q 1 hrtx-20250331.htm 10-Q 10-Q --12-31 Q1 0000818033 false HERON THERAPEUTICS, INC. /DE/ http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember http://www.herontx.com/20250331#CompanyChiefExecutiveOfficerMember 0000818033 hrtx:SignificantCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000818033 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember hrtx:ThirdLargestCustomerMember 2025-01-01 2025-03-31 0000818033 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000818033 hrtx:HerculesCapitalIncMember 2023-08-15 0000818033 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0000818033 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0000818033 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000818033 hrtx:SubleaseAgreementMember stpr:NC 2025-03-31 0000818033 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000818033 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000818033 hrtx:ForeignCommercialPaperMember 2024-12-31 0000818033 us-gaap:CommonStockMember 2021-05-31 0000818033 us-gaap:WarrantMember 2025-01-01 2025-03-31 0000818033 2023-08-15 2023-08-15 0000818033 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0000818033 us-gaap:CommonStockMember 2023-12-31 0000818033 hrtx:Short-TermSubleaseAgreementMember stpr:NC 2025-01-01 2025-03-31 0000818033 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000818033 hrtx:ZYNRELEFMember 2025-03-31 0000818033 us-gaap:OtherNoncurrentLiabilitiesMember 2025-03-31 0000818033 hrtx:AponvieMember 2025-03-31 0000818033 us-gaap:DomesticCorporateDebtSecuritiesMember 2025-03-31 0000818033 us-gaap:DebtInstrumentRedemptionPeriodTwoMember hrtx:SeniorUnsecuredConvertibleNotesMember 2021-05-01 2021-05-31 0000818033 hrtx:ForeignCommercialPaperMember 2025-03-31 0000818033 hrtx:SeniorUnsecuredConvertibleNotesMember 2021-05-01 2021-05-31 0000818033 hrtx:HerculesCapitalIncMember 2023-08-09 2023-08-09 0000818033 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0000818033 us-gaap:DebtInstrumentRedemptionPeriodOneMember hrtx:SeniorUnsecuredConvertibleNotesMember 2021-05-01 2021-05-31 0000818033 us-gaap:USTreasurySecuritiesMember 2025-03-31 0000818033 2025-05-01 0000818033 hrtx:SUSTOLMember 2025-03-31 0000818033 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000818033 hrtx:HerculesCapitalIncMember 2024-01-01 2024-03-31 0000818033 us-gaap:CommonStockMember 2024-03-31 0000818033 hrtx:HerculesCapitalIncMember 2025-03-31 0000818033 hrtx:AllowanceForRebatesAndChargebacksMember 2025-03-31 0000818033 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000818033 hrtx:AllowanceForDistributorFeesMember 2024-12-31 0000818033 us-gaap:ForeignCorporateDebtSecuritiesMember 2024-12-31 0000818033 stpr:CA 2025-03-31 0000818033 hr